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A B S T R A C T
Background
Angle-closure glaucoma is a leading cause of irreversible blindness in the world. Treatment is aimed at opening the anterior chamber
angle and lowering the IOP with medical and/or surgical treatment (e.g. trabeculectomy, lens extraction). Laser iridotomy works by
eliminating pupillary block and widens the anterior chamber angle in the majority of patients. When laser iridotomy fails to open
the anterior chamber angle, laser iridoplasty may be recommended as one of the options in current standard treatment for angle-
closure. Laser peripheral iridoplasty works by shrinking and pulling the peripheral iris tissue away from the trabecular meshwork. Laser
peripheral iridoplasty can be used for crisis of acute angle-closure and also in non-acute situations.
Objectives
To assess the effectiveness of laser peripheral iridoplasty in the treatment of narrow angles (i.e. primary angle-closure suspect), primary
angle-closure (PAC) or primary angle-closure glaucoma (PACG) in non-acute situations when compared with any other intervention.
In this review, angle-closure will refer to patients with narrow angles, PAC and PACG.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Group
Trials Register) (The Cochrane Library), MEDLINE, EMBASE and LILACS (Latin American and Caribbean Literature on Health
Sciences). The databases were last searched on 11 February 2008.
Selection criteria
Only randomised controlled trials (RCTs) were eligible for inclusion in this review. Patients with narrow angles, PAC or PACG were
eligible. Studies that included only patients with acute presentations, using laser peripheral iridoplasty to break acute crisis were excluded.
Data collection and analysis
No analysis was carried out due to lack of trials.
Main results
There were no RCTs assessing laser peripheral iridoplasty in the non-acute setting of angle-closure.
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Authors’ conclusions
There is currently no strong evidence for laser peripheral iridoplasty’s use in treating angle-closure.
P L A I N L A N G U A G E S U M M A R Y
Laser peripheral iridoplasty for angle-closure glaucoma
Angle -closure glaucoma is a leading cause of irreversible blindness in the world. Treatment is aimed at opening the drainage system
and lowering the pressure in the eye with medical and/or surgical treatment. Laser peripheral iridoplasty is used in patients with angle-
closure when other treatments fail to open the anterior drainage system. It works by shrinking and pulling the peripheral iris tissue
away from the trabecular meshwork. Due to the lack of randomised controlled trials, this review found no strong evidence for the use
of 0laser peripheral iridoplasty in the treatment of angle-closure.
B A C K G R O U N D
Angle-closure glaucoma is a leading cause of irreversible blindness
in the world. Treatment is aimed at opening the anterior chamber
angle and lowering the intraocular pressure (IOP) with medical
and/or surgical treatment (e.g. trabeculectomy, lens extraction).
Laser iridotomy works by eliminating pupillary block and widens
the anterior chamber angle in the majority of patients. When
laser iridotomy fails to open the anterior chamber angle, laser
iridoplasty may be recommended as one of the options in current
standard treatment for angle-closure. Laser peripheral iridoplasty
works by shrinking and pulling the peripheral iris tissue away from
the trabecular meshwork. Laser peripheral iridoplasty can be used
for crisis of acute angle-closure and also in non-acute situations.
Description of the condition
Glaucoma has been defined as a progressive optic neuropathy with
characteristic appearances of the optic discs and specific pattern
of visual field defects. Based on the appearance of the anterior
chamber angle it can be classified into open-angle or closed-angle
glaucoma. In the latter, an elevated IOP occurs as a consequence
of an obstruction of the outflow pathway located in the anterior
chamber angle (i.e. trabecular meshwork) by the peripheral iris.
Closure of the anterior chamber angle can be appositional (re-
versible) or synechial (permanent, due to adherent uveal tissue).
Among patients with appositional closure of the anterior cham-
ber angle, many have normal IOP without any signs of glaucoma.
They are usually described as having “narrow angles” or “primary
angle closure suspects”. If the IOP is elevated and/or there are parts
of the angle with synechial closure (but without signs of glaucoma-
tous damage), the preferred term is ’primary angle-closure’ (PAC).
The term ’primary angle-closure glaucoma’ (PACG) is reserved for
those patients with angle-closure and evidence of glaucomatous
optic disc damage and/or visual field loss. In this review, angle-
closure will refer to patients with narrow angles, PAC and PACG.
Primary angle-closure glaucoma is a leading cause of irreversible
blindness in the world. Sixty-seven million people worldwide are
affected by glaucoma. Open-angle glaucoma is more common
than PACG but the latter is more likely to result in bilateral blind-
ness (Quigley 1996; Resnikoff 2004). Primary angle-closure glau-
coma is more common in Asians and women. Foster et al esti-
mated that the number of persons with narrow angles in China,
based on previous studies in Mongolia (Foster 1996) and Singa-
pore (Foster 2000) is 28.2 million, while 9.1 million would have
angle-closure. Furthermore, of the 1.7 million persons bilaterally
blind from glaucoma in China, 91% are caused by PACG. Foster
et al concluded that PACGmight be the leading cause of glaucoma
blindness in the world today (Foster 2001).
Patients with angle-closure may present with acute symptoms of
highly elevated IOP but the majority of patients have a chronic
course with no symptoms in the early stages of the disease. In-
terventions for acute presentation of angle-closure are being eval-
uated in another Cochrane review and will not be considered in
this review.
Description of the intervention
Argon laser is applied using a contact lens (e.g. Abraham contact
lens) to the iris periphery, approximately six shots per quadrant.
The argon laser is typically set at 500-micron spot size, with a
duration of 0.5 seconds, and an initial starting laser energy of 50
to 200 mW. This laser energy level is gradually increased if iris
stromal shrinkage is not observed initially. It has been suggested
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that heat shrinkage of collagen may be responsible for the short-
term response to laser peripheral iridoplasty, and that contraction
of the fibroblastic membrane may be responsible for its long-term
effects (Sassani 1993). Laser peripheral iridoplasty can be used as
a primary treatment or after laser peripheral iridotomy for acute
angle-closure attacks.
How the intervention might work
Treatment of angle-closure is aimed at (1) opening the anterior
chamber angle, most commonly by laser iridotomy, and (2) low-
ering the IOP with medical and/or surgical treatment (e.g. tra-
beculectomy, lens extraction). Laser iridotomy works by elimi-
nating pupillary block and widens the anterior chamber angle in
the majority of patients, although in some of them the anterior
chamber angle remains closed. The latter situation may be due
to plateau iris syndrome or a prominent and thick peripheral iris.
When laser iridotomy fails to open the anterior chamber angle,
laser peripheral iridoplasty may be recommended as one of the
options in current standard treatment for angle-closure.
Laser peripheral iridoplasty tries to pull away and ’remove’ iris tis-
sue away from the trabecular meshwork by shrinking the periph-
eral iris tissue.
Why it is important to do this review
Laser peripheral iridoplasty is part of the standard treatment for
angle-closure and is indicated in patients who do not respond to
laser iridotomy. The use of laser peripheral iridoplasty appears to
be increasingly reported in the literature and among experts in
specialist meetings (Agarwal 1991; Lai 1999; Lam 1992; Weinreb
2006). So far, there has been no systematic review to assess the
effectiveness of laser peripheral iridoplasty in the treatment of eyes
with angle-closure in non-acute situations.
O B J E C T I V E S
The objective of this review was to assess the effectiveness of laser
peripheral iridoplasty in the treatment of eyes with angle-closure in
non-acute situations when compared with any other intervention
including observation, medical treatment, laser peripheral irido-
tomy or surgical interventions such as trabeculectomy or cataract
extraction.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials were eligible for inclusion in this
review. Trials included should have analysis based on one eye per
patient.
Types of participants
Patients with narrow angles, PAC or PACG were eligible. It was
anticipated that some trials would include patients with a previous
history of acute presentations while others would evaluate partic-
ipants with non-acute conditions only. Studies that included only
patients with acute presentations, using laser peripheral iridoplasty
to break the acute phase were excluded.We included studies which
had participants with a past history of an acute presentation but
had not had laser peripheral iridoplasty during the attack. There
were no restrictions with respect to previous treatments (i.e. pe-
ripheral iridotomy), age, gender, ethnicity or the number of par-
ticipants.
Types of interventions
We only included trials that compared laser peripheral iridoplasty
with or without medical treatment versus a control group without
laser peripheral iridoplasty and with similar management (obser-
vation or medical treatment).
Types of outcome measures
Primary outcomes
Conversion rates using life-table analysis (Kaplan Meier and Cox
hazard model) will be estimated. Conversion rates of a) or b) be-
tween one to five years follow up, based on survival data, will then
be reported.
a) From narrow angle (IOP < 21), to PAC (IOP
>
= 21), and/or
b) From PAC to PACG (with glaucomatous disc damage and/or
glaucomatous visual field damage; see below for definition).
Glaucomatous optic disc damage would include the presence of
thinning or “notching” of the neuroretinal rim, vertical enlarge-
ment of cup, or asymmetry greater than 0.2 in the cup-disc ratio
without differences in disc size or refractive error between eyes.
Glaucomatous visual field (VF) damage will be defined for
Humphrey perimeter as a reproducible defect in at least two con-
secutive and reliable VFs of (1) (a) two or more contiguous points
withP < 0.01 loss or greater, or (b) three ormore contiguous points
with P < 0.05 loss or greater, or (c) a 10-dB difference across the
nasal horizontal midline at two or more adjacent points in the to-
tal deviation plot; (2) a Glaucoma Hemifield Test (GHT) outside
normal limits in the same sector. For other perimeters, equivalent
criteria would be used.
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Secondary outcomes
Post-treatment the data below will be collected at all reported
times. From this data, the variable at one and five years post-
treatment will be used for data analysis.
(1) Intraocular pressure as measured by Goldmann’s (mmHg).
(2) Number of anti-glaucoma medications.
(3) Opening of the anterior chamber angle, determined clinically
by a masked clinician or with imaging technology.
(4) Any additional laser or surgical interventions for glaucoma.
(5) Best-corrected visual acuity.
(6) In patients with angle-closure glaucoma, any deterioration of
visual field loss. Any event analysis or trend analysis used by the
authors to measure visual field loss will be accepted.
(7) Quality of life measures will be tabulated if reported.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Tri-
als (CENTRAL) (which contains the Cochrane Eyes and Vision
Group Trials Register) (The Cochrane Library, Issue 1, 2008),
MEDLINE (January 1966 to February 2008), EMBASE (Jan-
uary 1980 to February 2008) and LILACS (Latin American
and Caribbean Literature on Health Sciences) (1982 to February
2008). There were no date or language restrictions in the electronic
search for trials. The databases were last searched on 11 February
2008.
See: Appendices for search strategies for each database.
Searching other resources
We searched the reference lists of retrieved articles for details of
further relevant studies. We did not handsearch journals or con-
ference proceedings specifically for this review.
Data collection and analysis
Selection of studies
Two authors independently assessed the titles and abstracts of all
reports identified by the electronic and manual searches. Each re-
port was labelled A (definitely exclude), B (unsure), or C (defi-
nitely include). Full text articles of abstracts labelled as ’unsure’
were reassessed according to the inclusion criteria for this review.
Studies labelled ’definitely exclude’ were excluded from the review.
Studies labelled as ’definitely include’ were assessed for method-
ological quality. We resolved any differences between the two au-
thors by discussion. No studies were identified that met our in-
clusion criteria.
Methods to be used in future updates to the review
As studies are identified in the future, they will be included in the
review using the following methods.
Data extraction and management
Two authors will extracte data independently using a paper form
developed by Cochrane Eyes and Vision Group. One author will
enter data into RevMan followed by the second author who will
enter the data using a double-data entry facility to verify the data
entered.
Assessment of risk of bias in included studies
As no RCTs were found that met our inclusion criteria, we briefly
described the case series reporting the effectiveness of laser periph-
eral iridoplasty (see below and Table 1).
Should any trials become available two authors will independently
assess the included studies for sources of systematic bias according
to the guidelines in Chapter 8 of the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2008). The studies will
be evaluated for the following criteria: allocation concealment (se-
lection bias), masking of outcome assessors (detection bias), and
rates of follow up and intention-to-treat analysis (attrition bias).
(a) Allocation concealment will be reported as ’adequate’, ’inade-
quate’ or ’unclear’. Any reasonable method of allocation conceal-
ment will be considered to be ’adequate’. If the adequacy of allo-
cation concealment is unclear from the trial report we will contact
the primary investigators for clarification. If they do not respond
within six weeks we will classify the study based on available in-
formation and update it as more information becomes available.
(b) Masking of outcome assessors will be noted. Masking of in-
vestigators and participants might not be possible with the inter-
ventions being examined and will not be assessed.
(c) Rates of followup, reason for loss to followupwill be examined.
(d) Masking of outcome assessors will be noted.
We will resolve disagreements through discussion and reach a con-
sensus. We will contact the authors of the studies for additional
information on issues that are categorised as ’unclear’ from infor-
mation available in the report. If there is a failure to communicate
with the primary investigators, or if they do not respond within a
reasonable period of time, we will assess the methodological qual-
ity based on the available information.
Measures of treatment effect
Data analysis will be done according to the guidelines set out
in Chapter 9 of the Cochrane Handbook for Systematic Reviews of
Interventions (Deeks 2008). Outcomes will be summarised as a
relative risk, or mean difference.
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Unit of analysis issues
Wewill only include studies with analysis on an one eye per patient
basis.
Dealing with missing data
We expect studies to be analysed on an intention-to-treat basis.
There will be concern regarding the validity of the study if there
is no information on the characteristics of the missing data or
whether this may introduce any bias. Where data are missing or
unclear, the authors will be contacted for clarification and further
information.
Assessment of heterogeneity
Should any trials become available we will attempt to quantify
the proportion of variability within included randomised studies
that is explained by heterogeneity using the I2 statistic (Higgins
2002). If the I2 statistic is greater than 50% we will consider it as
substantial heterogeneity and will not combine the study results in
a meta-analysis. Instead we will present the studies in a tabulated
or narrative summary.
Assessment of reporting biases
Selection, detection, performance and attrition biases will be as-
sessed as above. Funnel plots will be used to detect the presence
of any publication bias.
Data synthesis
Data analysis will be performed according to the guidelines set out
in Chapter 9 of the Cochrane Handbook for Systematic Reviews of
Interventions (Deeks 2008). Dichotomous outcomes will be sum-
marised as risk ratios and continuous outcomeswill be summarised
as a mean difference. Standardised mean difference will be calcu-
lated when outcomes are measured on different scales. If there is
no substantial heterogeneity as per the I2 statistic we will com-
bine the results of the included studies in a meta-analysis using
a random-effects model. We will use a fixed-effect model if there
are fewer than three studies. This is to avoid reporting potentially
poor effect estimates due to random-effects models in situations
with very few trials. Meta-analysis will be performed on the pri-
mary outcomes and difference in mean Goldmann IOP and its
standard error.
Sensitivity analysis
We will examine the impact of excluding studies with lower
methodological quality, unpublished data and industry funded
data in sensitivity analyses.
R E S U L T S
Description of studies
Results of the search
The searches were designed to include a filter to identify RCTs.
However, when the filter was applied the search retrieved very few
references. We decided to run the searches without the filters to
retrieve any type of study discussing the use of laser peripheral
iridoplasty for the treatment of angle- closure glaucoma.
The electronic searches retrieved 3 references from The Cochrane
Library, 79 references from MEDLINE, 68 references from EM-
BASE and 5 references from LILACS. After deduplication the
search identified a total of 96 references. The Trials Search Co-or-
dinator scanned the results and removed any references that were
not relevant to the scope of the review. The authors then excluded
twenty-seven references which assessed laser peripheral iridoplasty
in acute angle-closure glaucoma. Only two studies reported its use
in the non-acute setting but neither were RCTs nor case controlled
studies. Hence, no trials were available for further analysis.
Included studies
No trials were eligible for analysis. We found two case series
which assessed laser peripheral iridoplasty in angle-closure. One
described the long-term success rate of laser peripheral iridoplasty
in plateau iris syndrome in 23 eyes of 14 patients (Ritch 2004).
The other reports the functional success rate of laser peripheral
iridoplasty use after inferior 180° goniosynechialysis for PACG
with 360° peripheral anterior synechiae in five patients (Lai 2000).
These case series will be mentioned in the discussion section and
characteristics of these studies can be found in Table 1.
Risk of bias in included studies
This section will be completed when RCTs are included in the
review.
Effects of interventions
This section will be completed when RCTs are included in the
review.
D I S C U S S I O N
Literature surrounding the use of laser peripheral iridoplasty in
angle-closure is scarce. There are relatively more studies reporting
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its efficacy in breaking attacks of angle-closure where it can be used
in medically unbreakable attacks. However, in a recent consensus
meeting among glaucoma experts (Weinreb 2006) laser iridoplasty
was considered a standard treatment in patients with persistent
appositional angle-closure after peripheral iridotomy.
We have found only two studies which have reported the effective-
ness of laser peripheral iridoplasty in the non-acute setting. Ritch
et al carried out a retrospective case series involving 23 eyes of 14
patients (Ritch 2004). They had a mean follow up of 78.9 months
and found that in all patients the anterior chamber angle did open
after treatment, and only three eyes needed repeat laser peripheral
iridoplasty. They suggested that it is a safe and effective procedure
with a satisfactory long term success rate.
Laser peripheral iridoplasty’s use has also been reported post in-
ferior 180° goniosynechialysis for eyes with angle-closure. Lai et
al recruited five patients with PACG and 360° peripheral anterior
synechiae for inferior 180° goniosynechialysis (Lai 2000). Laser
peripheral iridoplasty was then applied on day four after surgery
and the functional success rate (defined as having an IOP of less
than 20 mmHg at last follow up) was observed in four patients.
The authors suggested that laser peripheral iridoplasty is a safe
and effective adjunct to goniosynechialysis for treatment of angle-
closure with total synechial angle-closure.
Although at present there is no strong evidence for the use of
laser peripheral iridoplasty in angle-closure, these two positive case
series and the consensus among experts suggest that it is worth
conducting a randomised study to determine its effectiveness in
angle-closure.
Summary of main results
There were no RCTs assessing laser peripheral iridoplasty in the
non-acute setting of angle-closure.
Overall completeness and applicability of
evidence
No strong evidence was found.
Quality of the evidence
There was no strong evidence for the use of laser peripheral irido-
plasty’s use in treating angle-closure.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Laser peripheral iridoplasty may be used for breaking attacks of
acute angle-closure if unresponsive tomedical therapy or successful
iridotomy.
It has been proposed to be effective in non-acute situations in
patients with angle-closure when laser iridotomy fails to open the
anterior chamber angle.
However, there is currently no strong evidence for its role in the
treatment of angle-closure.
Implications for research
Future trials will need to include patients with residual angle-clo-
sure after peripheral iridotomy. Laser iridoplasty should be com-
pared with a control group without this intervention. A RCT
would be the ideal study design. Comparison of argon laser idiro-
plasty with other interventions designed to open the anterior
chamber angle (e.g. lens extraction) in a randomised trial would
also be of interest. Description of the methods to examine the
anterior chamber angle, before and after intervention, would be
essential. If clinical examination is going to be used, standardis-
ation of grading would be important. The use of imaging tech-
niques (such as anterior segment optical coherence tomography
(OCT) or ultrasound biomicroscopy) would complement qualita-
tive evaluation of the anterior chamber angle and would be recom-
mended. Mid and long-term effectiveness would be measured in
terms of IOP, extension of anterior chamber angle-closure, visual
field changes, visual acuity, and vision-related quality of life. Out-
comes would need to be assessed by masked investigators. Stan-
dard ethical requirements would apply.
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Other studies assessing laser iridoplasty in non-acute ACG
Study name Methods Participants Intervention Outcomes
Lai 2000 prospective case series n=5 patients
with chronic angle-closure
inferior 180 goniosynechial-
ysis is followed by laser pe-
ripheral iridoplasty
intraocular pressure and
number of medications
Ritch 2004 retrospective case series n=14 patients
with plateau iris syndrome
treated with laser peripheral
iridoplasty
argon laser peripheral irido-
plasty
need of repeat laser periph-
eral iridoplasty or additional
means of intervention
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor Glaucoma, Angle-Closure
#2 glaucoma*
#3 angle* near close*
#4 narrow near angle*
#5 (#1 OR #2 OR #3 OR #4)
#6 iridoplast*
#7 (#5 AND #6)
Appendix 2. MEDLINE search strategy
1. exp clinical trial/ [publication type]
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
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13. exp glaucoma angle closure/
14. glaucoma$.tw.
15. (angle$ adj3 close$).tw.
16. (narrow adj3 angle$).tw.
17. or/13-16
18. iridoplast$.tw.
19. 17 and 18
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville et al (Glanville 2006)
Appendix 3. EMBASE search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.
14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$.tw.
17. random$.tw.
18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. exp closed angle glaucoma/
34. glaucoma$.tw.
35. (angle$ adj3 close$).tw.
36. (narrow adj3 angle$).tw.
37. or/33-36
38. “iridoplasty”/
39. argon laser peripheral iridoplasty/
40. iridoplast$.tw.
41. or/38-40
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42. 37 and 41
Appendix 4. LILACS search strategy
iridoplast$
WH A T ’ S N E W
Last assessed as up-to-date: 10 February 2008.
Date Event Description
24 April 2008 Amended Converted to new review format.
H I S T O R Y
Protocol first published: Issue 3, 2007
Review first published: Issue 3, 2008
Date Event Description
23 November 2007 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
Conceiving the review: AAB
Designing the review: AAB, WSN
Coordinating the review: WSN
Data collection for the review
- Designing search strategies: Cochrane Eyes and Vision Editorial Base
- Undertaking searches: Cochrane Eyes and Vision Editorial Base
- Screening search results: WSN, AAB, GSA
- Organising retrieval of papers: WSN
- Screening retrieved papers against inclusion criteria: WSN, AAB, GSA
- Appraising quality of papers: WSN, AAB, GSA
- Extracting data from papers: WSN, AAB, GSA
- Writing to authors of papers for additional information: AAB, WSN
- Providing additional data about papers: WSN, AAB
- Obtaining and screening data on unpublished studies: WSN
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Data management for the review
- Entering data into RevMan: WSN, AAB
- Analysis of data: AAB, WSN
Interpretation of data
- Providing a methodological perspective: AAB, WSN
- Providing a clinical perspective: AAB
- Providing a policy perspective: AAB
- Providing a consumer perspective: AAB
Writing the review: AAB, WSN
Providing general advice on the review: AAB
Securing funding for the review: AAB
Performing previous work that was the foundation of the current study: AAB
D E C L A R A T I O N S O F I N T E R E S T
None known.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The title was changed from chronic angle-closure glaucoma to angle-closure. Angle-closure refers to patients with narrow angles, angle-
closure and angle-closure glaucoma.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Laser Therapy; Glaucoma, Angle-Closure [∗surgery]; Iris [∗surgery]
MeSH check words
Humans
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